hybrid molecule

hybrid molecule

[′hī·brəd ′mäl·ə‚kyül]
(biochemistry)
A single molecule, usually protein, peculiar to heterozygotes and containing two structurally different polypeptide chains determined by two different alleles.
Mentioned in ?
References in periodicals archive ?
The ZoptEC pivotal Phase 3 trial is a fully-recruited (over 500 patients), open-label, randomized-controlled study, comparing the efficacy and safety of zoptarelin doxorubicin, a hybrid molecule composed of a synthetic peptide carrier and a wellCaeknown chemotherapy agent, doxorubicin, to doxorubicin alone.
AEZS-108 represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin.
Therefore, this is a true hybrid molecule, which appears to have arisen from recombinational events between porB2-99 and porB3-193 alleles.
In addition to the parental cell line preparation, which produced a moderate amount of BCAR1, the study included the transfectant 4A12, which overproduced BCAR1 (1), and transfectants that overproduced FLAG-tagged (Stratagene Europe) BCAR1 (FBCAR1), HEF1, and a FLAG-tagged hybrid molecule consisting of the first 63 amino acid residues of BCAR1 and residues 64-834 of HEF1 (F-Hybrid).
Phenalkamide: New Hybrid Molecule and Its Unique Coating Properties--Yun Mi Kim, Cardolite
The ZoptEC Phase 3 trial is an open-label, randomized-controlled study, comparing the efficacy and safety of zoptarelin doxorubicin, a hybrid molecule composed of a synthetic peptide carrier and a wellCaeknown chemotherapy agent, doxorubicin, to doxorubicin alone.
One did, quite convincingly - a hybrid molecule, which researchers named JQ1, for Qi.
The mix-up causes the cells to make a hybrid molecule consisting of parts of two separate immune system proteins, presumably because pieces of the proteins' respective genes have fused.
A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity.
18 SCIENCE that the fatty acid enabled the hybrid molecule to pass through the oily blood-brain barrier.
Immunex began a clinical trial of its hybrid molecule in July; Genetech plans clinical tests at an undisclosed time.
NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.

Full browser ?